German biotech MODAG received CPHI Milan's API Development and Innovation award for developing a CE-certified cerebrospinal fluid test that detects pathological alpha-synuclein aggregates alongside emrusolmin, a small molecule binding the same protein species. The drug is in a Phase 2 trial in multiple system atrophy run by Teva, with no efficacy results reported to date. The pairing illustrates a diagnostic-first approach to neurodegeneration, where confirming the underlying pathology precedes and defines treatment.
Key Points
- CE-certified CSF test detects pathological alpha-synuclein aggregates directly
- Emrusolmin targets same protein; Phase 2 trial ongoing in MSA
- No efficacy data reported; award recognizes approach, not outcomes
Longevity Analysis
Parkinson's has historically been diagnosed by the time motor symptoms appear, long after the underlying protein pathology has taken hold in neural tissue. Confirming the molecular lesion before symptoms dominate shifts intervention earlier, and it also cleans up trial populations that have confounded brain disease research for decades. Measuring the actual signal rather than inferring it from downstream behaviour is the prerequisite for any intervention aimed at preserving neural function over time — though the clinical value here remains unproven until the trial reads out.
Original published by Longevity.Technology, by Kyle Umipig.